iiinova — where your digital self keeps evolving

Therefore, 𝗳𝗼𝘂𝗿 𝗺𝗼𝗱𝘂𝗹𝗲𝘀 𝘄𝗲𝗿𝗲 𝗰𝗿𝗲𝗮𝘁𝗲𝗱 (three are already available), moving from 𝗯𝗮𝘀𝗶𝗰𝘀 𝗼𝗳 𝗥𝗪𝗗 𝗮𝗻𝗮𝗹𝘆𝘀𝗲𝘀 in regulatory decision-making to 𝗴𝗼𝗼𝗱 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 along the product lifecycle and a 𝗵𝗮𝗻𝗱𝘀-𝗼𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀.

100

One of Real4Reg’s goals was to develop training activities in data-driven decision-making for a variety of stakeholders, ranging from experts to patients.

100

🌟 “𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗳𝗼𝗿 𝗔𝗹𝗹: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗜𝗻𝘁𝗼 𝗢𝘂𝗿 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺” is a session that will be presented on 𝟯 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗮𝘁 𝟭𝟲:𝟰𝟱-𝟭𝟳:𝟭𝟬 𝗖𝗘𝗧. To know more about this topic, please visit Real4Reg's website. Here is a short description of the topics that will be addressed.

100

📢 𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 – 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗠𝗼𝗱𝘂𝗹𝗲𝘀 𝗦𝗲𝘀𝘀𝗶𝗼𝗻! Real4Reg will have its 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝟯-𝟰 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟲, 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻, 𝗣𝗼𝗿𝘁𝘂𝗴𝗮𝗹 (𝗵𝘆𝗯𝗿𝗶𝗱). The event will address the project’s results, lessons learnt, and insights on how RWD can strengthen regulatory and HTA decision-making.

100

🔗The 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗼𝗽𝗲𝗻. If you are interested in attending, please click here www.eventosinfarmed.pt/events/event.... The spots are limited, so make sure to secure yours! #Real4Reg #RWD #HorizonEurope #Research #Innovation

000

In this keynote, the 𝘀𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝘂𝘀𝗲 𝗼𝗳 𝗵𝗲𝗮𝗹𝘁𝗵 𝗱𝗮𝘁𝗮 will be the main focus, with topics such as the 𝘃𝗮𝗹𝘂𝗲, 𝘁𝗵𝗲 𝗯𝗮𝗿𝗿𝗶𝗲𝗿𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗶𝗺𝗽𝗮𝗰𝘁 on multiple stakeholders being discussed.

100

In 2022, the European Commission launched the European Health Data Space (EHDS) initiative, which ultimate purpose is to allow the 𝘂𝘀𝗲 𝗮𝗻𝗱 𝗲𝘅𝗰𝗵𝗮𝗻𝗴𝗲 𝗼𝗳 𝗵𝗲𝗮𝗹𝘁𝗵 𝗱𝗮𝘁𝗮 𝗳𝗿𝗼𝗺 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗻𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵 𝗿𝗲𝗰𝗼𝗿𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗨𝗻𝗶𝗼𝗻.

100

The speaker will be Giulia Ancillotti (DG Sante) and if you would like to know more about her, please visit Real4Reg’s website. Here is a short description of the topics that will be presented.

100

🌟“𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗮𝘁𝗮 𝗦𝗽𝗮𝗰𝗲 (𝗘𝗛𝗗𝗦): 𝗥𝗲𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗨𝘀𝗲 𝗼𝗳 𝗦𝗲𝗰𝗼𝗻𝗱𝗮𝗿𝘆 𝗗𝗮𝘁𝗮” is a keynote regarding this wonderful initiative. It will be presented on 𝟯 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗮𝘁 𝟭𝟬:𝟰𝟱-𝟭𝟭:𝟮𝟱 𝗖𝗘𝗧.

100

📢𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 – 𝗘𝗛𝗗𝗦 𝗞𝗲𝘆𝗻𝗼𝘁𝗲! Real4Reg will have its 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝟯-𝟰 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟲, 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻, 𝗣𝗼𝗿𝘁𝘂𝗴𝗮𝗹 (𝗵𝘆𝗯𝗿𝗶𝗱). The event will address the project’s results, lessons learnt, and insights on how RWD can strengthen regulatory and HTA decision-making.

100

🔗Real4Reg would like to thank to all of the sister projects for the great collaboration and we are looking forward to discussing the recommendations. If you would like to access the publication, click here: ascpt.onlinelibrary.wiley.com/doi/10.1002/....

100

To improve the 𝘂𝘀𝗲 𝗼𝗳 𝗥𝗪𝗗 𝗮𝗻𝗱 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗱𝗮𝘁𝗮 𝗶𝗻 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗛𝗧𝗔 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴, some 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 were also formulated for important stakeholders, focusing on areas like 𝗱𝗮𝘁𝗮 𝗮𝗰𝗰𝗲𝘀𝘀, 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲, 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝘆, 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻𝘃𝗼𝗹𝘃𝗲𝗺𝗲𝗻𝘁.

100

🌟In this publication, the 𝗰𝗼𝗺𝗺𝗼𝗻 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 of the six projects was compiled.

100

This scientific article results from the joint efforts of the MetReal cluster, which include Insafedare Project, More-EUROPA, ONCOVALUE, REALM_EU, and REDDIE-Diabetes, besides Real4Reg.

100

📢𝗡𝗲𝘄 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻! Real4Reg is excited to announce the publication of the joint MetReal cluster manuscript "𝗧𝗼𝘄𝗮𝗿𝗱 𝘁𝗵𝗲 𝗨𝘀𝗲 𝗼𝗳 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗗𝗮𝘁𝗮 𝗳𝗼𝗿 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗛𝗧𝗔 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗠𝗮𝗸𝗶𝗻𝗴: 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗱 𝗥𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗿𝗼𝗺 𝗦𝗶𝘅 𝗘𝗨-𝗙𝘂𝗻𝗱𝗲𝗱 𝗣𝗿𝗼𝗷𝗲𝗰𝘁𝘀".

100

The conference was a great opportunity to share Real4Reg's work within the scientific community and gain further input as we head into the final phase of the project. Photo credits: Oliver Kuß #Real4Reg #HorizonEurope #RWD #Research #Innovation

000

🌟Finally, Martin Russek gave a talk summarising the 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 𝗮𝗻𝗱 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗯𝗲𝘁𝘁𝗲𝗿 𝘂𝘀𝗲 𝗼𝗳 𝗥𝗪𝗗 𝗶𝗻 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗛𝗧𝗔 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗮𝗸𝗶𝗻𝗴 that we collected within the MetReal cluster.

100

🌟Christoph Röthlein gave a poster presentation on the 𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗥𝗪𝗗 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗰𝗼𝗻𝗰𝗲𝗽𝘁, which is already available here real4reg.ehs-webmanager.de/registration....

100

Excitingly, Stefanie Lanzinger from our sister project REDDIE-Diabetes complemented Anna's presentation with a practical application of the TMLE method from their project.

100

Her talk was part of a workshop on 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗖𝗼𝘅 𝗽𝗿𝗼𝗽𝗼𝗿𝘁𝗶𝗼𝗻𝗮𝗹 𝗵𝗮𝘇𝗮𝗿𝗱𝘀 𝗺𝗼𝗱𝗲𝗹, organised by members of the Bundesinstitut für Arzneimittel und Medizinprodukte Real4Reg team.

100

🌟Anna Malewski presented the 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗺𝗮𝘅𝗶𝗺𝘂𝗺 𝗹𝗶𝗸𝗲𝗹𝗶𝗵𝗼𝗼𝗱 𝗲𝘀𝘁𝗶𝗺𝗮𝘁𝗶𝗼𝗻 (𝗧𝗠𝗟𝗘) 𝗺𝗲𝘁𝗵𝗼𝗱 𝗶𝗻 𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗱𝗲𝗲𝗽 𝗹𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗺𝗼𝗱𝗲𝗹 𝗗𝗲𝗲𝗽𝗛𝗶𝘁 as a way to analyse survival data.

110

📢𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗮𝘁 𝗗𝗚𝗘𝗽𝗶 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴! Last week, some Real4Reg researchers attended the 𝗮𝗻𝗻𝘂𝗮𝗹 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝘁𝗵𝗲 𝗚𝗲𝗿𝗺𝗮𝗻 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗳𝗼𝗿 𝗘𝗽𝗶𝗱𝗲𝗺𝗶𝗼𝗹𝗼𝗴𝘆 (DGEpi Deutsche Gesellschaft für Epidemiologie e.V.) to present Real4Reg project outputs.

100

If the participants correctly answer to some questions about the modules, they can receive a 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗲 𝗼𝗳 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗶𝗼𝗻. 🔗If you would like to 𝘀𝘁𝗮𝗿𝘁 𝘁𝗵𝗶𝘀 𝘁𝗿𝗮𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗮𝗺, click here real4reg.ehs-webmanager.de/registration.... #Real4Reg #HorizonEurope #RWD #Research #Innovation

000

The training program is intended for all stakeholder groups involved in decision-making, including 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗛𝗧𝗔 𝗲𝘅𝗽𝗲𝗿𝘁𝘀, 𝗽𝗮𝘆𝗲𝗿𝘀, 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗮 𝗮𝗻𝗱 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝘃𝗲𝘀, 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

100

The third module provides 𝗴𝗼𝗼𝗱 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 and in the fourth the participants will be able to 𝗮𝗽𝗽𝗹𝘆 𝘁𝗵𝗲 𝗮𝗹𝗴𝗼𝗿𝗶𝘁𝗵𝗺𝘀 𝗶𝗻 𝗮 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗱𝗮𝘁𝗮𝘀𝗲𝘁. The majority of the modules are already available and until the end of the year all of them will become accessible.

100

This training concept on data-driven decision-making was created based on the expertise, results, and lessons learnt over Real4Reg's course. 🌟Module 1 provides 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗼𝗿𝘆 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 about RWE use in regulatory decision-making, while Module 2 focuses on the 𝗯𝗮𝘀𝗶𝗰𝘀 𝗼𝗳 𝗰𝗼𝗺𝗺𝗼𝗻 𝗱𝗮𝘁𝗮 𝗺𝗼𝗱𝗲𝗹𝘀.

100

📢𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗥𝗪𝗗 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗠𝗼𝗱𝘂𝗹𝗲𝘀! Real4Reg developed 𝗳𝗼𝘂𝗿 𝘁𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗺𝗼𝗱𝘂𝗹𝗲𝘀 (divided in eight submodules) regarding the 𝘂𝘀𝗲 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗥𝗪𝗗 𝗶𝗻 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗮𝗻𝗱 𝗛𝗧𝗔 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴.

101

🔗 The 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗼𝗽𝗲𝗻. If you are interested in attending, please click here www.eventosinfarmed.pt/events/event.... The 𝘀𝗽𝗼𝘁𝘀 𝗮𝗿𝗲 𝗹𝗶𝗺𝗶𝘁𝗲𝗱, so make sure to secure yours! #Real4Reg #RWD #HorizonEurope #Research #Innovation

000

This session will be moderated by Dirk De Valck (EUpALS) and a 𝗿𝗼𝘂𝗻𝗱𝘁𝗮𝗯𝗹𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 with Christine Leopold (Utrecht University) will take place.

100

RWD-based ECA to complement preauthorisation evidence in rare disease with limited therapeutic options is a promising area of regulatory interest. Can RWD deliver on this promise?

100

After describing 𝗔𝗟𝗦 𝗲𝗽𝗶𝗱𝗲𝗺𝗶𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗰𝗼𝘂𝗿𝘀𝗲, Real4Reg attempted to construct an 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗮𝗿𝗺 (𝗘𝗖𝗔) 𝗳𝗼𝗿 𝗮 𝗵𝘆𝗽𝗼𝘁𝗵𝗲𝘁𝗶𝗰𝗮𝗹 𝗔𝗟𝗦 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝘁𝗿𝗶𝗮𝗹.

100

Here is a short description of the topics that will be discussed. In contrast to primary cancers, there is more 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗔𝗟𝗦 𝗮𝗰𝗿𝗼𝘀𝘀 𝗥𝗪𝗗 𝘀𝗼𝘂𝗿𝗰𝗲𝘀. ALS is a rapidly fatal disease with limited treatment options.

100

The speakers will be Vera Ehrenstein (Aarhus University), Monika Korcinska (DKMA), and Mohamed Aborageh (Fraunhofer SCAI) and if you would like to know more about them, please visit Real4Reg’s website.

100

🌟 “𝗔𝗺𝘆𝗼𝘁𝗿𝗼𝗽𝗵𝗶𝗰 𝗟𝗮𝘁𝗲𝗿𝗮𝗹 𝗦𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀: 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗶𝗻𝗴 𝗥𝗪𝗗 𝗮𝗻𝗱 𝗠𝗟 𝗶𝗻 𝗧𝗵𝗲 𝗣𝗿𝗲𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘀𝗮𝘁𝗶𝗼𝗻 𝗣𝗵𝗮𝘀𝗲” is a session that will be presented on 𝟯 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗮𝘁 𝟭𝟱:𝟯𝟬-𝟭𝟲:𝟯𝟬 𝗖𝗘𝗧.

100

📢 𝗥𝗲𝗮𝗹𝟰𝗥𝗲𝗴 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 – 𝗔𝗺𝘆𝗼𝘁𝗿𝗼𝗽𝗵𝗶𝗰 𝗟𝗮𝘁𝗲𝗿𝗮𝗹 𝗦𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀 𝗦𝗲𝘀𝘀𝗶𝗼𝗻! Real4Reg will have its 𝗙𝗶𝗻𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝟯-𝟰 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟲, 𝗶𝗻 𝗟𝗶𝘀𝗯𝗼𝗻, 𝗣𝗼𝗿𝘁𝘂𝗴𝗮𝗹 (𝗵𝘆𝗯𝗿𝗶𝗱). The event will address the project’s results, lessons learnt, and insights on how RWD can strengthen regulatory and HTA decision-making.

100

000

This session will be moderated by António Lourenço (IPO Lisboa) and a 𝗿𝗼𝘂𝗻𝗱𝘁𝗮𝗯𝗹𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 with Olga Kholmanskikh (FAMHP) and Andrea De Censi (Champalimaud Foundation) will take place.

100

Focusing on breast cancer in men, the 𝗳𝗲𝗮𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗼𝗳 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗱𝗮𝘁𝗮 for this rare patient subpopulation will be explored.

100

The session will start by describing 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗰𝗼𝘂𝗿𝘀𝗲 𝗼𝗳 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 using RWD from Denmark, Finland, and Portugal. Results from 𝗱𝗮𝘁𝗮 𝗵𝗮𝗿𝗺𝗼𝗻𝗶𝘀𝗲𝗱 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗢𝗠𝗢𝗣 common data model will be benchmarked against native-format results.

100

𝗠𝗲𝗻 𝘄𝗶𝘁𝗵 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗿𝗲 𝗿𝗮𝗿𝗲 𝗮𝗻𝗱 𝗵𝗮𝘃𝗲 𝘄𝗼𝗿𝘀𝗲 𝗽𝗿𝗼𝗴𝗻𝗼𝘀𝗶𝘀 𝘁𝗵𝗮𝗻 𝘄𝗼𝗺𝗲𝗻. Among patients with breast cancer, RWD sources may differ in the degree of 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘀𝘁𝗶𝗰𝘀, 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗽𝗿𝗼𝗴𝗻𝗼𝘀𝗶𝘀.

100

Here is a short description of the topics that will be discussed. Typical of primary malignancies, breast cancer is well recorded in RWD sources via compulsory cancer registration. Breast cancer is the most common female malignancy, with well-developed treatment protocols.

100

The speakers will be Vera Ehrenstein (Aarhus University), Monika Korcinskaa (DKMA), and Mohamed Aboragehh (Fraunhofer SCAI) and if you would like to know more about them, please visit Real4Reg’s website.

100

🌟 “𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗦𝘁𝘂𝗱𝘆𝗶𝗻𝗴 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗖𝗼𝘂𝗿𝘀𝗲 𝗮𝗻𝗱 𝗨𝘀𝗶𝗻𝗴 𝗦𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗗𝗮𝘁𝗮 𝗳𝗼𝗿 𝗨𝗻𝗱𝗲𝗿𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝗦𝘂𝗯𝗴𝗿𝗼𝘂𝗽𝘀” is a session that will be presented on 𝟯 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗮𝘁 𝟭𝟯:𝟬𝟱-𝟭𝟰:𝟬𝟱 𝗖𝗘𝗧.

100